Biotech & Healthcare Archives - Vista Partners LLC

Italy’s Chiesi Group’s $1.9 Billion KalVista Buy: A Rare-Disease Power Play With Real Teeth -( $XBI $IBB )

by John F. Heerdink, Jr. 1 day ago 203Views 0Likes

On a gray April morning better suited to defensive sectors than bold moves, Italy’s Chiesi Group decided to do the opposite and write a $1.9 billion check for KalVista Pharmaceuticals, a specialist in oral therapies for hereditary angioedema (HAE). The deal, struck…

Eli Lilly’s Strategic Shopping Spree Signals a New Era in Biotech Consolidation -( $LLY $XBI $IBB )

by John F. Heerdink, Jr. 1 day ago 128Views 0Likes

In a market where capital efficiency has become the new currency of credibility, Eli Lilly & Co. (LLY) appears to be writing a decidedly modern playbook for growth—one acquisition at a time. The Indianapolis-based pharmaceutical heavyweight has quietly assembled a portfolio of…

Eli Lilly Just Hired an Algorithm: Inside the $2.25 Billion AI Drug Whisperer Deal With Profluent -( $LLY $IBB $XBI )

by John F. Heerdink, Jr. 1 day ago 205Views 0Likes

Eli Lilly’s (LLY) latest AI move reads less like a side project and more like a statement: the drugmaker is quietly trying to turn biology into software—and it just hired Profluent as one of its lead engineers. Lilly Bets Big On AI-Authored…

Healthcare’s Quiet Rally: Incyte, Pfizer & Eupraxia Put Some Spring in Wall Street’s Step – ( $EPRX $INCY $PFE $XBI )

by John F. Heerdink, Jr. 2 days ago 312Views 0Likes

Health care may not have the meme-stock glamour of AI chips, but this spring the sector is quietly reminding investors why 'boring' can be beautiful. A trio of updates from Incyte (INCY), Pfizer (PFE) and Eupraxia Pharmaceuticals (NASDA: EPRX) is painting a…

Not Just Chips and Giggles: Pairing High‑Flying Tech With Serious Healthcare Winners -( $AI $AMD $CAH $CVS $EPRX $MODD $JNJ $NVDA $PODD $TNDM )

by John F. Heerdink, Jr. April 24, 2026 403Views 0Likes

Investors are quietly building a new playbook: keep riding the AI rocket, but pair it with old‑economy resilience and under‑the‑radar healthcare innovators that actually move the needle in patients’ lives. When Tech Flies Too Close to the Sun Wall Street’s love affair…

Is Nanobiotix Building a Toll Road for Genetic Drugs? Early Preclinical Data Says “Maybe” -( $NBTX $JNJ $IBB $XBI )

by John F. Heerdink, Jr. April 23, 2026 316Views 0Likes

Nanobiotix’s (NBTX) latest preclinical data suggest that its Nanoprimer technology may do for lipid nanoparticle (LNP) DNA immunotherapy what noise-cancelling headphones did for air travel: make a powerful experience markedly more tolerable. For investors watching the crossroad of oncology and genetic medicines,…

An Applied $7.5 Billion Signal From the Heartland -( $APLD $CRWV $GOOG )

by John F. Heerdink, Jr. April 23, 2026 221Views 0Likes

Applied Digital’s (NASDAQ: APLD) latest mega-lease reads less like a data-center contract and more like a sovereign-infrastructure plotline for the AI age, and that is precisely where Seven Boson Group’s sovereign AI lab vision strides onto the stage. A $7.5 Billion Signal From…

Precision Meets Possibility: Inside Tribe Public’s Latest CEO Event on Targeted Alpha Therapy with NAYA

by John F. Heerdink, Jr. April 21, 2026 252Views 0Likes

In a market often dominated by macro noise and earnings volatility, Tribe Public’s latest CEO Presentation and Q&A Webinar Event offered something far rarer: a glimpse into the future of cancer treatment—and perhaps, a pathway to curing it. The event, titled “Can…

From Waistlines to Warheads: How GLP‑1 Cash Is Quietly Fueling the Radiopharma Revolution -( $AZN $BMY $LLY )

by John F. Heerdink, Jr. April 20, 2026 187Views 0Likes

Eli Lilly is turning its GLP-1 windfall into a broader oncology and radiopharma push, just as a new generation of targeted alpha therapies steps onto center stage with companies like NAYA Therapeutics — and investors are starting to notice that “weight loss”…

From Shopping Carts to Smart Carts: Walmart’s Digital Health Push Meets Lilly’s GLP‑1 Boom – ( $AMGN $LLY $MODD $NVO $PFE $WMT )

by John F. Heerdink, Jr. April 20, 2026 122Views 0Likes

Walmart’s (WMT) latest move into digital health reads less like a retail side-hustle and more like an opening bell in the next leg of the GLP‑1 trade, with syringes, smartphones, and stock tickers all lining up on aisle 7. As weight‑loss drugs…

Biotech & Healthcare

Your Guide To Staying Informed In The Markets